The recently published Pharmacy Market Review 2025 by Christie & Co offers a clear picture of how community pharmacy across the UK is changing. While the report covers all four nations, its findings are particularly relevant for Scotland as we face our own challenges in workforce, funding, and service delivery. Understanding how trends in England and elsewhere affect Scotland will be crucial for shaping our national response.
Market Overview: A Shifting Landscape
Across the UK, the total number of community pharmacies continues to fall. As of March 2025, there were 90 fewer trading pharmacies compared with the previous year, a decline of around 0.6 percent. Scotland saw a smaller reduction of 0.3 percent but remains affected by similar pressures on costs, staffing, and workload.
Independent ownership continues to rise as large multiples reshape their portfolios. The divestment of outlets by Boots and other national operators has created opportunities for smaller pharmacy groups and first-time buyers. For Scotland, this trend could signal both renewed entrepreneurial activity and the need for new models of local support to ensure these businesses remain sustainable.
Prescription volumes continue to grow across the UK. England recorded a rise of around four percent between 2023 and 2025, reaching 1.26 billion items. Increased dispensing activity has also been recorded across Scotland. However, the review makes clear that higher item numbers do not automatically lead to better financial outcomes. Rising costs for staff, premises, and energy continue to squeeze margins for many contractors.

Funding and Contractual Environment
The major development for England this year was the new funding settlement between the Department of Health and Social Care, NHS England, and Community Pharmacy England. The Community Pharmacy Contractual Framework was set at just over £3 billion for 2025 to 2026, with an increase in the Single Activity Fee from £1.27 to £1.46. Although the uplift was welcomed, it is only a one-year deal and many in the sector believe it will not fully cover rising costs or historic underfunding.
Scotland operates under a separate NHS framework, but these changes matter. English funding decisions shape political expectations and influence national comparisons. There is a real risk that Scottish pharmacy could fall behind in relative investment if similar increases are not secured. The funding model in Scotland must keep pace with inflation, workforce pressures, and the growing demand for clinical services.
Workforce and Locum Pressures
Workforce issues remain one of the greatest challenges across the UK. The review reports that the average pharmacist salary rose by more than 12 percent in 2024, reaching over £50,000 per year. National Insurance increases and inflation have added further strain to budgets. Locum costs have also been volatile. Across the UK, rates have fallen by around five percent, with the Scottish average now close to £36 per hour. This slight reduction offers temporary relief to employers but may create new recruitment difficulties, especially in rural and island communities where locum cover is essential.
Scotland’s geography makes these pressures more complex. Travel costs, housing shortages, and professional isolation can deter pharmacists from working in remote areas. Long-term solutions will require targeted investment in training, career progression, and retention packages to maintain an equitable pharmacy service across the country.


Expanding Clinical Services
The Pharmacy Market Review highlights that future growth will depend on service delivery, not just dispensing. In England, the Pharmacy First service, launched in early 2024, has already delivered nearly five million consultations for seven common conditions. The review notes that more than half of those consultations came from GP or NHS 111 referrals. This demonstrates that pharmacy-based clinical care can relieve pressure on primary care and improve patient access.
Scotland already operates its own successful Pharmacy First Scotland service, but there is still room to expand its scope, digital integration, and public awareness. Building on England’s experience could help accelerate development of independent prescribing roles, improve referral pathways, and ensure that pharmacy continues to play a central part in NHS Scotland’s ambitions for community care.
Private and preventative services are also growing areas of interest. Across the UK, demand for health checks, vaccination, travel health, and weight management support has increased sharply. Many Scottish contractors are already exploring these areas to diversify income streams and strengthen their role within local health networks.
Technology, Investment, and Innovation
Innovation remains a vital focus. The review found that 36 percent of UK pharmacy owners plan to invest in automation, and one in three intend to convert additional consultation space. These investments help improve workflow, reduce error risk, and create more time for clinical services. For Scotland, with a high proportion of rural and independent pharmacies, practical support for digital transformation could have major benefits in efficiency and resilience.
At the same time, the UK is seeing tighter rules on online and distance selling pharmacies. In England, no new Distance Selling Pharmacy contracts will be granted after June 2025, and existing ones will face restrictions on in-person service delivery later in the year. Scotland has not announced comparable changes, but regulators will be watching closely. Balancing access, safety, and local sustainability will remain a key question for the future.
Market Sentiment and Transactions
Despite the pressures, the market remains active. The report shows that 76 percent of pharmacy sales in the first half of 2025 were asset sales, with the remainder as share sales. Average completion times are now around 36 weeks, and prices achieved are close to 90 percent of the original asking value. Demand remains particularly strong among small groups and first-time buyers.
Survey data from more than 7,000 professionals reveals a divided mood. Around half of respondents felt pessimistic about the sector’s short-term outlook, but most agreed that demand for pharmacy-based clinical and private services is rising. That underlying demand provides a strong case for optimism, especially if funding and workforce strategies can be stabilised.

Conclusion
The Pharmacy Market Review 2025 portrays a sector in transition. Across the UK, community pharmacy continues to adapt to shifting patient expectations, rising costs, and expanding clinical responsibilities. For Scotland, the opportunity lies in shaping these changes around our own strengths, including a well-established national service framework, an experienced workforce, and a commitment to accessible local care.
Sustained funding, digital investment, and support for innovation will be critical. By learning from developments elsewhere in the UK while focusing on Scotland’s distinct needs, community pharmacy can emerge stronger, more resilient, and better equipped to meet the health challenges of the decade ahead.
Thanks to the team at Christie & Co as well as Locate A Locum for producing such a vital market update.






